Average Rate on a 30-Year Mortgage in the US Falls to 6.69%
The average rate on a 30-year mortgage in the U.S. eased again this week, slipping to its lowest level since late October
All Posts in "News Team"
ReNeuron joins exodus from AIM exchange after missing fundraising goal
ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself from the costs and regulatory obligations of the exchange.
Allist pays Jacobio $21M for KRAS drug combo, landing leading role in Chinese cancer race
Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million Chinese yuan ($21 million) for rights to a near-approval inhibitor of the oncogene and a potentially complementary molecule.
Another of NuCana’s retooled chemotherapies is unable to increase survival in the clinic
NuCana has seen another of its reworked chemotherapies struggle to prove itself in the clinic, halving the biotech’s stock in post-market trading.
FDA’s drug center to consolidate AI efforts under single council
The FDA’s Center for Drug Evaluation and Research (CDER) is consolidating its artificial-intelligence-related activities under a single AI Council, in part in response to efforts from the Biden administration to ensure the safety and security of machine learning software.
In 2 papers, researchers piece together how micronuclei in cancer cells collapse and contribute to disease progression
In 2022, on the alpine shores of Lake Maggiore in northern Italy, longtime friends Samuel Bakhoum, M.D., Ph.D., and Stefano Santaguida, Ph.D., were catching up. Pandemic restrictions had prevented the two from seeing each other for years, but, at a small conference in the lakeside town of Stresa, they seized the opportunity to share what they’d been working on recently—the collapse of micronuclei in cancer cells.
Qiagen, AstraZeneca expand companion diagnostic partnership to chronic diseases beyond cancer
Qiagen and AstraZeneca are expanding their diagnostics partnership, with plans to explore the use of genomic profiling in chronic diseases beyond cancer.
Gain hopes to prove Parkinson’s drug’s potential next year after phase 1 win for allosteric modulator
Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a phase 1 trial.
J&J files for FDA approval of $6.5B autoimmune drug, teeing up showdown with argenx and UCB
Johnson & Johnson has taken another step toward realizing a return on its $6.5 billion nipocalimab bet, filing for FDA approval to challenge argenx and UCB for the generalized myasthenia gravis (gMG) market.
Losses in China Lead to $5 Billion Charge for General Motors as It Cuts the Value of Its Assets
The poor performance of General Motors’ Chinese joint ventures is forcing the company to write down assets and take a restructuring charge totaling more than $5 billion in the fourth quarter of this year
Edgewise’s stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
Aligos’ MASH prospect slashes liver fat in phase 2, but stock drops anyway
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
Achilles drops cell therapy program, braces for layoffs after missing ‘commercial viability’ goals
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform
How the Stock Market Defied Expectations Again This Year, by the Numbers
US Applications for Unemployment Benefits Hold Steady, but Continuing Claims Rise to 3-Year High